Development of an integrated digital health intervention to promote engagement in and adherence to medication for opioid use disorder
Abstract Background Buprenorphine-naloxone is an evidence-based treatment for Opioid Use Disorder. However, despite its efficacy, nearly half of participants are unsuccessful in achieving stabilization (i.e., period of time following medication induction in which medication dose is adjusted to be ef...
Main Authors: | Kirsten J. Langdon, Susan Ramsey, Caroline Scherzer, Kate Carey, Megan L. Ranney, Josiah Rich |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-04-01
|
Series: | Addiction Science & Clinical Practice |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13722-020-00189-4 |
Similar Items
-
Hospitalist perspectives on buprenorphine treatment for inpatients with opioid use disorder
by: Megan K Reed, et al.
Published: (2022-12-01) -
Operational definition of precipitated opioid withdrawal
by: Kelly E. Dunn, et al.
Published: (2023-04-01) -
Low barrier medication for opioid use disorder at a federally qualified health center: a retrospective cohort study
by: Jamie Carter, et al.
Published: (2022-11-01) -
Receipt of medications for opioid use disorder among youth engaged in primary care: data from 6 health systems
by: Sarah M. Bagley, et al.
Published: (2021-07-01) -
Methadone Maintenance Therapy (MMT) and Alternatives in Opioid Use Disorder: Reviewing the latest advancements, outcomes, and challenges in substitutional therapy for opioid addiction - literature review
by: Karolina Koszyczarek, et al.
Published: (2024-02-01)